Mankind Pharma net profit dropped 16% YoY to Rs 385 crore in Q3FY25 led by higher expenses. The company reported revenue from operations at Rs. 3,230 Cr, up by 24% YoY.The adjusted EBITDA rose 46% YoY to Rs 895 crore. Adjusted EBITDA margin of 26.9% up by 210 bps YoY. Domestic revenue at Rs 2773 crore, up 17%, exports more than doubled to Rs 457 crore. The market share of Mankind has increased in the domestic formulation market from 4.4% in March 2024 to 4.8% as of December 2024 on account of BSV acquisition.The consumer health segment grew 30% YoY in Q3FY25 supported by steady growth across all key brands like Manforce Condom, Gas-o-fast and HealthOk which grew 13%, 28% and 26% YoY respectively.